Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (4115)	6/13/2001 8:23:17 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 52153

>> Did anyCEO learned anything from LKST case? << The mergers that we've seen recently? Many are "LKST-like" in spirit, if not in effect. How many companies could add that sort of "basics plus pipeline" punch? I have two decent-size positions in companies that could be considered to be "chemistry plus pipe" types. But, I can't find more (in the public realm). CRA clearly got their munch smarts from Corixa, rather than from Millennium. But, the spirit was correct and I guess that they're praying for luck among the current clinical candidates?? Seems to me -- first blush -- that the Coelacanth munch has some foresight behind it, on behalf of both parties. Who would be your munchers?